One of the portfolio companies in the negotiations does not require a merger against cash consideration contingent on objectives, impact on revenues, equity and cash in the company’s reports Post published:21/11/2021
In a binding distribution agreement with CD’X (held approximately 5.5%) you will receive exclusivity to market CD’X products Post published:31/10/2021
CARDIACSENSE Cardiacsense (about 5.55%) – Completion of processing of experimental results of the medical watch Cardiacsense2, Post published:03/08/2021
EFA E.F.A experimental results for white blood cell counts using the RevDx device Post published:29/06/2021
CARDIACSENSE Cardiacsense (approximately 5.57%), in an exclusive distribution agreement in Brazil for the sale of medical watches to detect heart rhythm disorders – correction of the company’s holding rate Post published:13/06/2021
